Active — Not RecruitingEarly Phase 1

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

United States48 participantsStarted 2017-06-12

Plain-language summary

The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the disease.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have evidence of soft tissue disease OR
✓. If they only have osteomedullary disease at protocol enrollment, they should have:

What they're measuring

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Timeframe: 2 years

response rate (CR+PR)

Timeframe: 2 years

Trial details

NCT IDNCT03189706

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

View on ClinicalTrials.gov More Neuroblastoma (NB) trials